A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among ...

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

It's a very busy and spooky Halloween eve today — several companies had big misses in earnings reported this morning. Let's ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55 ...

Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Eli Lilly & Co. said that a small change in dosing its Alzheimer’s drug Kisunla cut patients’ rate of brain-swelling side ...

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug ...

Eli Lilly's Alzheimer's drug Kisunla, under late-stage trials, shows promising interim results with a gradual dosing schedule, reducing serious brain swelling cases. The trial, which is under review ...